• Profile

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis: A nationwide cohort study from the DANBIO and DERMBIO registries

Seminars in Arthritis and Rheumatism Feb 15, 2022

In this study, varying treatment responses to drugs with various types of action across rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA) and psoriasis highlight the requirement for an individualized treatment approach, that considers the underlying disease, patient profile, and treatment history, despite the fact that these disease conditions have many overlaps in their pathogenesis.

  • In this nationwide cohort study using the prospective nationwide registries DANBIO and DERMBIO, researchers assessed the real-life drug survival of biologics and novel small-molecule therapies across various disease conditions such as RA, AxSpA, PsA, and psoriasis.

  • Participants were 12,089 patients (17,903 treatment series) in total, including 5,104 RA patients (7,867 series), 2,157 AxSpA patients (3,016 series3), 2,551 PsA patients (3,313 series), and 2,577 psoriasis patients (3,707 series).

  • In RA, highest drug survival was evident for rituximab followed by baricitinib, etanercept and tocilizumab respectively, in confounder-adjusted models.

  • In AxSpA, drug survival was shown to be high for golimumab than all other drugs, followed by secukinumab and etanercept and was lowest for infliximab.

  • Drug survival in PsA was the lowest for tofacitinib and infliximab relative to all other drugs.

  • Almost equally good performance was displayed by all other drugs, with a tendency of a generally higher drug survival for golimumab, followed by secukinumab and ixekizumab.

  • Guselkumab had the highest drug survival in psoriasis.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen